Moyamoya Disease Market: Roadmap to Win and Drive Customer Value
Market Highlights:
Moyamoya disease
(MMD) is a rare, cerebrovascular disorder which occurs due to blocked arteries
at the base of the brain i.e. the basal ganglia. The MMD primarily affects
children, but it can also occur in adults.
A number of
factor such as growing public awareness, technological advancements, rising
prevalence of neurological disorders, increasing awareness, improving
regulatory framework, increasing government assistance, increasing adoption
rate, and rising funding and reimbursement policies are propelling the growth
of the global moyamoya disease market.
However,
challenges in research and development, side-effects of treatment, the high
cost of treatment, the presence of misbranded and spurious drugs and poor
healthcare system in low and middle-income countries may hamper the growth of
the market over the review period.
It is estimated
that the Moyamoya
Disease Market is expected to grow at a CAGR of 7.0%
during the forecast period 2017-2023.
Key Players
·
Abbott Laboratories
·
Medtronic plc
·
Boston Scientific Corporation
·
Cordis Corporation
·
Koninklijke Philips N.V.
·
GE Healthcare
·
Siemens
·
Stryker
·
Genentech Inc.
·
Merck & Co. Inc
·
UCB Pharma Ltd
·
Sanofi
Segmentation
·
The global moyamoya disease market is segmented on the basis of
diagnosis, treatment, and distribution channels.
·
On the basis of the diagnosis, the market is classified as a
cerebral angiogram, magnetic resonance imaging (MRI), magnetic resonance
angiogram (MRA), computed tomography (CT) scans, transcranial Doppler
ultrasound, positron emission tomography (PET) scan, and electroencephalography
(EEG).
·
On the basis of the treatment, the market is classified as
surgical treatment and non-surgical treatment. The surgical treatment is
further classified as pial synangiosis, indirect procedures, and direct
arterial bypass.
·
On the basis of the distribution channel, the market is segmented
into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and
others
Regional Analysis
The Americas
dominate the moyamoya disease market owing to the rising awareness among
people, and high healthcare expenditure. According to the Centers for Disease
Control and Prevention in 2015, the total health expenditure in the United
States was reported to be USD 3.2 trillion and hospital care accounted for a
share of 32.3%.
Europe holds the
second position in the moyamoya disease market. It is expected that the support
provided by the government bodies for research & development and
improvement in the reimbursement policies in the healthcare is likely to drive
the market of Europe region.
The Asia Pacific
is the fastest growing moyamoya disease market owing to a huge patient pool and
developing healthcare technology. Healthcare expenditure is also improving in
various Asia Pacific countries.
According to the
Australian Institute of Health and Welfare in the years 2015-2016, the total
health expenditure was USD 170.4 billion, which is 3.6% higher than the
expenditure of 2014-2015.
The Middle East
& Africa holds the lowest market due to lack of technical knowledge and
poor medical facilities.
Comments
Post a Comment